NEWS & EVENTS

Latest news and upcoming events

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
20 Mar 2024

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
01 Dec 2011

Ysios Capital Partners and “la Caixa” lead MedLumics €3.5million/$4.7million Series A Financing.

MADRID - December 1, 2011 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the closing of a 3.5 million Euro/4.7 million USD Series A financing.
01 Dec 2011

Ysios Capital Partners and “la Caixa” lead MedLumics €3.5million/$4.7million Series A Financing.

MADRID - December 1, 2011 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the closing of a 3.5 million Euro/4.7 million USD Series A financing.
Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma<
13 Sep 2011

Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma

The oversubscribed series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners.
13 Sep 2011

Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma

Barcelona, Spain, 13 September 2011 – Ysios Capital Partners, the Spanish life sciences venture capital firm, today announces that is has led the €29.2 million Series D financing of AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) as a treatment of severe inflammatory diseases.
15 Jun 2011

Ysios Capital Partners leads €2million series A financing of STAT Diagnostica

Barcelona 15th June 2011 - Ysios Capital Partners today announces that it has led a €2M Series A investment in STAT Diagnostica, a company based in the Barcelona Science Park.
24 Jan 2011

Amgen to acquire Biovex for up to $1 bn

THOUSAND OAKS, Calif., and WOBURN, Mass. (Jan. 24, 2011) – Amgen (NASDAQ: AMGN) and BioVex Group, Inc. today announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, Inc., a privately held, venture-funded, biotechnology company headquartered in Woburn, Mass. BioVex is developing OncoVEXGM-CSF, a novel oncolytic vaccine in Phase 3 clinical development, that may represent a new approach to treating melanoma and head and neck cancer.
21 Sep 2010

Ysios Capital Partners leads €5million Series A Financing of Sabirmedical

Ysios Capital Partners leads € 5 Million
21 Sep 2010

Ysios Capital Partners leads €5million Series A Financing of Sabirmedical

BARCELONA 23th September 2010. Ysios Capital Partners today announces that it has led the Series A investment of Sabirmedical, company based in the Barcelona Science Park developing medical devices and sensor technologies.
10 May 2010

Ysios Capital Partners participates in Cardoz’ €10million Series A financing round.

Cardoz AB, a clinical stage company, today announced that it has closed a series A financing round of SEK 100 million (€ 10 million) with an international syndicate of venture capital investors.
10 May 2010

Ysios Capital Partners participates in Cardoz’ €10million Series A financing round.

Cardoz AB, a clinical stage company, today announced that it has closed a series A financing round of SEK 100 million (€ 10 million) with an international syndicate of venture capital investors.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360